Brief: Quantum Genomics Enters Exclusive Agreement With Qilu Pharmaceutical
19/10/2020 07:08
Oct 19 (Reuters) - Quantum Genomics SA ALQGC.PA :
* QUANTUM GENOMICS ENTERS INTO EXCLUSIVE LICENSING AND
COLLABORATION AGREEMENT WITH QILU PHARMACEUTICAL
* UNDER TERMS OF AGREEMENT, QILU PHARMACEUTICAL WILL RECEIVE
EXCLUSIVE COMMERCIALIZATION RIGHTS TO FIRIBASTAT IN GEATER CHINA
REGION
* QUANTUM GENOMICS WILL RECEIVE UPFRONT AND MILESTONE
PAYMENTS
AMOUNTING UP TO $50 MILLION, PLUS DOUBLE-DIGIT ROYALTIES ON
SALES
Source text for Eikon: ID:nGNX3P35rT
Further company coverage: ALQGC.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Quantum Genomics SA
See all newsBrief: Quantum Genomics Announces Resumption Of Discussions With HealthTech, Terminates Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics Enters Into Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics To Reduce Staff; Jean-Philippe Milon Becomes President and CEO
Brief: Quantum Genomics In Talks For New Strategic Project
Brief: Quantum Genomics Announces Lack Of Significant Efficacy For Firibastat In Their Phase Iii Study